24 March 2021: Clinical Research
Contribution of Interstitial Cells of Cajal to Gastrointestinal Stromal Tumor Risk
Qi Wang 1ABEG* , Zhen-peng Huang 2ACDEF** , Yu Zhu 3B , Fei Fu 1B , Lin Tian 1ABDG*DOI: 10.12659/MSM.929575
Med Sci Monit 2021; 27:e929575
Table 2 ICCs-specific immuno-marker characteristics in GISTs patients.
| Tumor site | CD117/c-kit positive# | CD34 positive* | CD117/c-kit and CD34 positive§ |
|---|---|---|---|
| Esophagus | 3 (100.00%) | 3 (100.00%) | 3 (100.00%) |
| Stomach | 84 (96.55%) | 81 (93.10%) | 80 (91.95%) |
| Small intestine | 10 (71.43%) | 11 (78.57%) | 10 (71.43%) |
| Colon and rectum | 7 (100.00%) | 6 (85.71%) | 6 (85.71%) |
| Omentum and mesentery | 10 (100.00%) | 9 (90.00%) | 9 (90.00%) |
| Liver | 1 (100.00%) | 1 (100.00%) | 1 (100.00%) |
| Overall | 115 (94.26%) | 111 (90.98%) | 109 (89.34%) |
| # χ=15.617; =0.008; * χ=3.751; =0.586; § χ=5.921; =0.314. The rate of CD117-positive cells was lower in tumors located in the small intestine than in tumors located in the colon and rectum, or stomach (χ=15.617; =0.008). The rate of CD34-positive cells was higher in tumors located in the stomach than in tumors located in the small intestine (χ=3.751; =0.586). The rate of both CD117/c-kit and CD34-positive cells was higher in tumors located in the esophagus and stomach than in tumors located in the small intestine (χ=5.921; =0.314). Moreover, the number of CD34-positive cells was lower as compare to the number of CD117-positive cells. | |||